Protalix BioTherapeutics

PLX

PLX
Protalix BioTherapeutics Stock Quote
$0.22 -$0.00 -1.1%
BATS BZX Real Time Price as of November 11, 2019, 4:00 p.m. EST View Interactive PLX Charts

A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system.

News & Analysis: Protalix BioTherapeutics

All

The Simplest Biotech Growth Portfolio Ever

Why play the clinical guessing game when attempting to tap into the growth of the biotech industry? Companies such as Amgen, Ligand Pharmaceuticals, Protalix, and Repligen are tapping into long term trends without much of the risk.


Is This Orphan Drugmaker in Trouble?

Protalix’s joint venture with Pfizer to bring a new Gaucher disease treatment to the market has had a rough start. Is the company doomed to be buried by its entrenched rivals, Sanofi and Shire?


Can Protalix Revolutionize This Orphan Disease?

The latest results in Protalix's pipeline may be from a phase 1 trial, but don't let that fool you. If successful, PRX-112 could run laps around Shire and Sanofi and catch the attention of larger partners, including Pfizer.






4 Longshot Stocks to Invest In

These companies are stuffed full of potential, but may be lacking in the results department. They could still pay off for investors.


This Week in Biotech

A look back at the biggest stories this week in biotech and what they mean for investors.



Interactive Chart